Lyon manufacturing facility returns to the Vectura Group
The facility currently manufactures seven oral products for the Group's partners.
Vectura Group has confirmed that, as expected, the lease of its manufacturing facility and oral product business in Saint-Quentin-Fallavier, Lyon, France to Aenova France expired on 30 June 2016. The facility transferred back to the Group upon expiry.
The facility currently manufactures seven oral products for the Group's partners. Five products use the Geomatrix family of technologies: Diclofenac-ratiopharm-uno, Coruno, ZYFLO CR, Madopar DR/Prolopa and Sular, whilst Lodotra/RAYOS uses the Geoclock chronotechnology. The facility also manufactures one other oral product, Triglide, based on the Group's solubilisation technology. In addition, there are currently a number of pipeline projects in development, including the first complex oral generic under the Group's strategic partnership with Hikma Pharmaceuticals. The facility has cGMP status, with approvals from the European Medicines Agency, the FDA, ANVISA (Brazil) and KFDA (South Korea) amongst others.
A number of initiatives are underway to maximise the value of the facility now that it has returned to the Group's control, leveraging proven capabilities in multilayer tableting, oral technology innovation and the high quality manufacturing capacity at the Lyon site.
David Lescuyer, Executive Vice President, Oral Business, commented: "We are very pleased that the Lyon facility returns to the Group at this exciting time. We have a strong high quality base with the return of the facility and we are confident of growing the business and creating future value by working with existing and new partners and leveraging our proven innovation and technology."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.